𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence

✍ Scribed by Laurent Azoulay; Sophie Dell’Aniello; Laetitia Huiart; Guillaume Galbaud du Fort; Samy Suissa

Publisher
Springer US
Year
2010
Tongue
English
Weight
207 KB
Volume
126
Category
Article
ISSN
0167-6806

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Risk of early recurrence among postmenop
Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen
✍ Hagen Kennecke; Heather McArthur; Ivo A. Olivotto; Caroline Speers; Chris Bajdik 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 162 KB 👁 1 views

## Abstract ## BACKGROUND Adjuvant aromatase inhibitors (AIs), instead of or after tamoxifen, are effective in decreasing recurrence in postmenopausal women with estrogen receptor (ER)‐positive breast cancer. An understanding of which patients are at risk of early recurrence while they are receivi